KVUE

Kenvue’s shares rose 39.7% last year, bringing its current price of $19.88 under scrutiny. A discounted cash flow estimate is being used to assess whether the stock still trades at fair value.

SUMMIT, N.J., October 21, 2026--Kenvue Inc. (NYSE: KVUE) will announce its third quarter 2026 financial results before the market opens on October 30, 2026. Due to the pending transaction with Kimberly-Clark, Kenvue will not be hosting a quarterly conference call to review its financial results.

The headline indicates that China has approved Kimberly‑Clark’s acquisition of Kenvue, clearing a major antitrust hurdle.

Kenvue will soon report its third‑quarter earnings. Analysts expect the company’s bottom line to stay flat.

Kimberly-Clark Corporation (NASDAQ: KMB) ("Kimberly-Clark") announced today that the requisite number of consents have been received to adopt certain proposed amendments (the "Amendments") with respect to all outstanding notes of Kenvue Inc. (NYSE: KVUE) ("Kenvue").

The EU Commission has approved Kimberly‑Clark’s acquisition of Kenvue, pending full compliance with the commitments offered by Kimberly‑Clark.

While nervous investors obsess over a handful of tech giants propping up the whole market, one portfolio manager keeps funneling fresh cash into the brands sitting in every American medicine cabinet, and the reasoning might make you rethink your own staples strategy.

Toward the end of the October 1 lightning round of Mad Money, a caller asked about Kimberly-Clark Corporation (NASDAQ:KMB) and its pending acquisition of Kenvue Inc. (NYSE:KVUE). They highlighted Kimberly-Clark’s difficult stock performance, low earnings multiple and high dividend yield. Jim Cramer replied: Okay, so I’m going to tell you, one, I think it’s a […]